Letter in Response to the Review by De Maria et al. 2014
(Source: Combination Products in Therapy)
Source: Combination Products in Therapy - June 3, 2014 Category: Drugs & Pharmacology Source Type: research
Foster ®: A High-Efficiency Combination Metered Dose Inhaler with Consistent Particle Size Distribution at Alternative Flow Rates
ConclusionConsistent particle size distribution of both active drug components delivered from Foster MDI at flow rates of 28 –30 and 60 L/min is observed. (Source: Combination Products in Therapy)
Source: Combination Products in Therapy - February 1, 2014 Category: Drugs & Pharmacology Source Type: research
Foster ® : A High-Efficiency Combination Metered Dose Inhaler with Consistent Particle Size Distribution at Alternative Flow Rates
ConclusionConsistent particle size distribution of both active drug components delivered from Foster MDI at flow rates of 28 –30 and 60 L/min is observed. (Source: Combination Products in Therapy)
Source: Combination Products in Therapy - February 1, 2014 Category: Drugs & Pharmacology Source Type: research
Foster ® : A High-Efficiency Combination Metered Dose Inhaler with Consistent Particle Size Distribution at Alternative Flow Rates
Conclusion
Consistent particle size distribution of both active drug components delivered from Foster MDI at flow rates of 28–30 and 60 L/min is observed. (Source: Combination Products in Therapy)
Source: Combination Products in Therapy - February 1, 2014 Category: Drugs & Pharmacology Source Type: research
Foster®: A High-Efficiency Combination Metered Dose Inhaler with Consistent Particle Size Distribution at Alternative Flow Rates
Conclusion
Consistent particle size distribution of both active drug components delivered from Foster MDI at flow rates of 28–30 and 60 L/min is observed. (Source: Combination Products in Therapy)
Source: Combination Products in Therapy - February 1, 2014 Category: Drugs & Pharmacology Source Type: research
Evolution of Coronary Stents: From Bare-Metal Stents to Fully Biodegradable, Drug-Eluting Stents
AbstractCoronary stenting represents the standard of care for percutaneous revascularization of symptomatic coronary artery disease. However, despite progress in the evolution of intravascular stents, clinical adverse events such as restenosis and stent thrombosis still represent the “achilles heel” of this ground-breaking technology. Of particular note was the association of these adverse events with the material, the polymer coating, and the active drug of currently approved drug eluting stents. Consequently, modifications were made to the design, coating, and the choice o f drugs, eventually, resulting in (fully) bi...
Source: Combination Products in Therapy - December 1, 2013 Category: Drugs & Pharmacology Source Type: research
Abatacept and Mycophenolate Mofetil Combination Therapy in Refractory Pediatric Systemic Lupus Erythematosus: A Case Series
ConclusionThe data suggest that combination therapy with ABA + MMF may be an alternative option in refractory pSLE nephritis. Additional studies are needed in pSLE to further assess the efficacy of this combination treatment. (Source: Combination Products in Therapy)
Source: Combination Products in Therapy - December 1, 2013 Category: Drugs & Pharmacology Source Type: research
Fine Particle Profile of Fluticasone Propionate/Formoterol Fumarate Versus Other Combination Products: the DIFFUSE Study
DiscussionThe FP/FORM suspension aerosol produced a high and consistent FPF of approximately 40% across both flow rates. The consistent FPF in vitro may be predictive of FP/FORM providing more consistent drug dosing in vivo, helping to counteract variable lung dose due to variation in inspiratory flow rate among patients and between a patient ’s day-to-day or successive inhalation maneuvers. (Source: Combination Products in Therapy)
Source: Combination Products in Therapy - December 1, 2013 Category: Drugs & Pharmacology Source Type: research
Stribild, a Single Tablet Regimen for the Treatment of HIV Disease
ConclusionStribild had a favorable safety profile in the two recently published randomized, double-blind, phase 3 clinical trials. With the approval of Stribild, clinicians now have more flexibility in prescribing single-tablet regimens for patients. (Source: Combination Products in Therapy)
Source: Combination Products in Therapy - December 1, 2013 Category: Drugs & Pharmacology Source Type: research
Combination of Cytotoxic Drugs for Patients with HER2-Negative Metastatic Breast Cancer
AbstractIn the last few decades the approach to metastatic breast cancer (MBC) treatment using chemotherapy, either as single or combination agents, has been largely studied and a wide spectrum of therapeutic options is now available. Anthracyclines and taxanes remain the cornerstone of treatment in this setting. The choice of combination chemotherapy versus monochemotherapy is still open to debate since results from clinical trials are, unfortunately, conflicting. Despite improvements in response and disease-free survival rates, there has been no overall survival benefit reported although toxicity is increased. Therefore,...
Source: Combination Products in Therapy - December 1, 2013 Category: Drugs & Pharmacology Source Type: research
Evolution of Coronary Stents: From Bare-Metal Stents to Fully Biodegradable, Drug-Eluting Stents
Abstract
Coronary stenting represents the standard of care for percutaneous revascularization of symptomatic coronary artery disease. However, despite progress in the evolution of intravascular stents, clinical adverse events such as restenosis and stent thrombosis still represent the “achilles heel” of this ground-breaking technology. Of particular note was the association of these adverse events with the material, the polymer coating, and the active drug of currently approved drug eluting stents. Consequently, modifications were made to the design, coating, and the choice of drugs, eventually, res...
Source: Combination Products in Therapy - December 1, 2013 Category: Drugs & Pharmacology Source Type: research
Abatacept and Mycophenolate Mofetil Combination Therapy in Refractory Pediatric Systemic Lupus Erythematosus: A Case Series
Conclusion
The data suggest that combination therapy with ABA + MMF may be an alternative option in refractory pSLE nephritis. Additional studies are needed in pSLE to further assess the efficacy of this combination treatment. (Source: Combination Products in Therapy)
Source: Combination Products in Therapy - December 1, 2013 Category: Drugs & Pharmacology Source Type: research
Fine Particle Profile of Fluticasone Propionate/Formoterol Fumarate Versus Other Combination Products: the DIFFUSE Study
Discussion
The FP/FORM suspension aerosol produced a high and consistent FPF of approximately 40% across both flow rates. The consistent FPF in vitro may be predictive of FP/FORM providing more consistent drug dosing in vivo, helping to counteract variable lung dose due to variation in inspiratory flow rate among patients and between a patient’s day-to-day or successive inhalation maneuvers. (Source: Combination Products in Therapy)
Source: Combination Products in Therapy - December 1, 2013 Category: Drugs & Pharmacology Source Type: research
Stribild, a Single Tablet Regimen for the Treatment of HIV Disease
Conclusion
Stribild had a favorable safety profile in the two recently published randomized, double-blind, phase 3 clinical trials. With the approval of Stribild, clinicians now have more flexibility in prescribing single-tablet regimens for patients. (Source: Combination Products in Therapy)
Source: Combination Products in Therapy - December 1, 2013 Category: Drugs & Pharmacology Source Type: research
